Anticancer Drugs 2021 Jul 12. Epub 2021 Jul 12.
Department of Urology Clinical Laboratory, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou Center for Medical Experiments, University of Chinese Academy of Science-Shenzhen Hospital, Shenzhen, Guangdong Institute of Genetic, Zhejiang University School of Medicine, Hangzhou, Zhejiang Institute of Biotherapy, School of Biotechnology, Southern Medical University, Guangzhou, Guangdong, China.
Everolimus, an oral mammalian target of rapamycin complex 1 (mTORC1) inhibitor, presents a therapeutic option in metastatic renal cell carcinoma (RCC) patients who were intolerant to, or previously failed, immune- and vascular endothelial growth factor-targeted therapies. However, the onset of drug resistance limits its clinical use. One possible mechanism underpinning the resistance is that inhibiting mTORC1 by everolimus results in mTORC2-dependent activation of v-Akt murine thymoma viral oncogene (AKT) and upregulation of hypoxia-inducible transcription factors (HIF). Read More